Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 14.83
CEMP's Cash-to-Debt is ranked lower than
54% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CEMP: 14.83 )
Ranked among companies with meaningful Cash-to-Debt only.
CEMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.12  Med: 8.88 Max: No Debt
Current: 14.83
Equity-to-Asset 0.77
CEMP's Equity-to-Asset is ranked higher than
62% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CEMP: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
CEMP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.77 Max: 0.82
Current: 0.77
0.48
0.82
Piotroski F-Score: 3
Altman Z-Score: -1.08
Beneish M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -548.72
CEMP's Operating Margin % is ranked lower than
73% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CEMP: -548.72 )
Ranked among companies with meaningful Operating Margin % only.
CEMP' s Operating Margin % Range Over the Past 10 Years
Min: -650.58  Med: -469.86 Max: -325.6
Current: -548.72
-650.58
-325.6
Net Margin % -551.45
CEMP's Net Margin % is ranked lower than
74% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CEMP: -551.45 )
Ranked among companies with meaningful Net Margin % only.
CEMP' s Net Margin % Range Over the Past 10 Years
Min: -654.76  Med: -490.79 Max: -333.65
Current: -551.45
-654.76
-333.65
ROE % -58.83
CEMP's ROE % is ranked lower than
68% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CEMP: -58.83 )
Ranked among companies with meaningful ROE % only.
CEMP' s ROE % Range Over the Past 10 Years
Min: -101.98  Med: -86.25 Max: -58.83
Current: -58.83
-101.98
-58.83
ROA % -46.87
CEMP's ROA % is ranked lower than
67% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CEMP: -46.87 )
Ranked among companies with meaningful ROA % only.
CEMP' s ROA % Range Over the Past 10 Years
Min: -191.64  Med: -60.35 Max: -46.87
Current: -46.87
-191.64
-46.87
ROC (Joel Greenblatt) % -190175.86
CEMP's ROC (Joel Greenblatt) % is ranked lower than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CEMP: -190175.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CEMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -190175.86  Med: -47223.9 Max: -18139.82
Current: -190175.86
-190175.86
-18139.82
3-Year Revenue Growth Rate 10.50
CEMP's 3-Year Revenue Growth Rate is ranked higher than
59% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CEMP: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CEMP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 10.5
Current: 10.5
0
10.5
3-Year EBITDA Growth Rate 16.80
CEMP's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CEMP: 16.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CEMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.7  Med: -64.5 Max: 21.2
Current: 16.8
-67.7
21.2
3-Year EPS without NRI Growth Rate 15.20
CEMP's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CEMP: 15.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CEMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.3  Med: -66.4 Max: 19.3
Current: 15.2
-69.3
19.3
GuruFocus has detected 1 Warning Sign with Cempra Inc $CEMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CEMP's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CEMP Guru Trades in Q2 2016

Jim Simons 205,300 sh (+576.89%)
George Soros Sold Out
» More
Q3 2016

CEMP Guru Trades in Q3 2016

Mario Gabelli 53,400 sh (New)
Jim Simons Sold Out
» More
Q4 2016

CEMP Guru Trades in Q4 2016

Paul Tudor Jones 213,600 sh (New)
Jim Simons 611,200 sh (New)
Mario Gabelli 38,600 sh (-27.72%)
» More
Q1 2017

CEMP Guru Trades in Q1 2017

Jim Simons 1,680,500 sh (+174.95%)
Mario Gabelli 28,700 sh (-25.65%)
Paul Tudor Jones 82,700 sh (-61.28%)
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ELVAF, NAS:IMDZ, NAS:FBIO, NAS:MNOV, NAS:CASC, NAS:VRNA, NAS:CDXS, NAS:KURA, NAS:CORI, NAS:NYMX, NAS:CMRX, NAS:STML, NAS:ENZY, NAS:ARDX, NAS:MDGL, NAS:PIRS, NAS:ABUS, OTCPK:SPHRY, NAS:NVLN, NAS:CLSN » details
Traded in other countries:9C1.Germany,
Headquarter Location:USA
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.

Cempra is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications. The company operates three segments, including contract research, license, and supply. Cempra generates most of its revenue through its contract research and license segments.

Top Ranked Articles about Cempra Inc

Cempra Presents Data on Ophthalmic Solithromycin at ARVO
Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update
Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
Cempra to Report First Quarter 2017 Financial Results
Cempra Withdraws Solithromycin Marketing Authorization Application in Europe

—Company plans to resubmit MAA with additional data, in alignment with FDA strategy—

CHAPEL HILL, N.C., March 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases, today announced that the company has withdrawn its marketing authorization application (MAA) seeking European Medicines Agency (EMA) approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults.
Based on the Day 120 questions Cempra received from the EMA, the company believes additional data would be required. By withdrawing the MAA at this time, Cempra will conserve considerable financial resources, and it will allow the company to align its strategy to provide additional data to both the EMA and U.S. Food and Drug Administration (FDA) to support potential approval. “Our goal is to make solithromycin available in the EU to address an important unmet medical need. We believe the most efficient path to approval is to withdraw the MAA at this time and to resubmit it with the additional data requested by the FDA,” said David Zaccardelli, Pharm.D., acting chief executive officer of Cempra. If approved, solithromycin would be the first new oral and IV antibiotic available in the EU in more than 15 years. According to the European Respiratory Society (ERS), more than 3,000,000 cases of community-acquired pneumonia are diagnosed each year in the EU, resulting in approximately 1,000,000 hospitalizations annually. The ERS notes that antibiotic resistance is one of the major threats undermining the treatment of respiratory infections. About Cempra, Inc. Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin has been evaluated in two phase 3 clinical trials for community-acquired bacterial pneumonia (CABP). Cempra is currently seeking approval for both intravenous and oral capsule formulations from the U.S. Food and Drug Administration. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Solithromycin is also in development for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Fusidic acid is Cempra's second product candidate, which has completed a phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI). Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is also studying solithromycin for ophthalmic conditions and has synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com. Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: our ability to address the issues identified by the FDA in the complete response letter relating to our new drug applications for solithromycin for community acquired bacterial pneumonia; our anticipated capital expenditures and our estimates regarding our capital requirements, including the costs of addressing the complete response letter;  our ability to obtain FDA and foreign regulatory approval of solithromycin as a treatment for community-acquired bacterial pneumonia; our and our strategic commercial partners’ ability to obtain FDA and foreign regulatory approval of our product candidates; and results of our and our strategic commercial partners' pre-clinical studies and clinical trials, which are not predictive of results from subsequent clinical trials for any possible therapy. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.
Contact:

John Bluth
Cempra, Inc.
(984) 209-4534
[email protected]

Read more...
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options

CHAPEL HILL, N.C., March 13, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases, today announced that the company has retained Morgan Stanley & Co. LLC as financial advisor to the company and to lead its recently announced process to review strategic business options.
The goal of this process is for Cempra to determine the best use of its significant cash resources and clinical programs to deliver value to patients and shareholders through internal and/or potential external opportunities. As of December 31, 2016, Cempra had cash and equivalents of $231.6 million. The company has not set a timetable for this process. No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic business options will result in any transaction, or the terms or timing of any potential transaction. The company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or otherwise determined that further disclosure is appropriate. About Cempra, Inc. Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin has been evaluated in two phase 3 clinical trials for community-acquired bacterial pneumonia (CABP). Cempra is currently seeking approval for both intravenous and oral capsule formulations from the U.S. Food and Drug Administration and the European Medicines Agency. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Solithromycin is also in development for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Fusidic acid is Cempra's second product candidate, which has completed a phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI). Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is also studying solithromycin for ophthalmic conditions and has synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com. Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the risk that we may be unable to identify, negotiate, enter into or consummate strategic business transactions on terms favorable to us or at all; our and our strategic partners’ prospects; our ability to obtain FDA and foreign regulatory approval of solithromycin as a treatment for community-acquired bacterial pneumonia; our and our strategic commercial partners' ability to obtain FDA and foreign regulatory approval of our product candidates; and results of our and our strategic commercial partners' pre-clinical studies and clinical trials, which are not predictive of results from subsequent clinical trials for any possible therapy. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.
Contact:
John Bluth
Cempra, Inc.
(984) 209-4534
[email protected]

Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
(858) 356-5932
[email protected]

Media Contacts:
Melyssa Weible
Elixir Health PR
(201) 723-5805
[email protected]


Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.24
CEMP's PB Ratio is ranked higher than
90% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CEMP: 1.24 )
Ranked among companies with meaningful PB Ratio only.
CEMP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 6.12 Max: 20.33
Current: 1.24
0.8
20.33
PS Ratio 9.85
CEMP's PS Ratio is ranked higher than
55% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CEMP: 9.85 )
Ranked among companies with meaningful PS Ratio only.
CEMP' s PS Ratio Range Over the Past 10 Years
Min: 7.91  Med: 46.63 Max: 76.63
Current: 9.85
7.91
76.63
EV-to-EBIT -0.12
CEMP's EV-to-EBIT is ranked higher than
96% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CEMP: -0.12 )
Ranked among companies with meaningful EV-to-EBIT only.
CEMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.3  Med: -6.9 Max: 0.6
Current: -0.12
-26.3
0.6
EV-to-EBITDA -0.12
CEMP's EV-to-EBITDA is ranked higher than
97% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CEMP: -0.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
CEMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.3  Med: -6.9 Max: 0.6
Current: -0.12
-26.3
0.6
Current Ratio 8.88
CEMP's Current Ratio is ranked higher than
71% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CEMP: 8.88 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s Current Ratio Range Over the Past 10 Years
Min: 2.48  Med: 9.54 Max: 30.34
Current: 8.88
2.48
30.34
Quick Ratio 8.88
CEMP's Quick Ratio is ranked higher than
72% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CEMP: 8.88 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s Quick Ratio Range Over the Past 10 Years
Min: 2.48  Med: 9.54 Max: 30.34
Current: 8.88
2.48
30.34
Days Sales Outstanding 114.49
CEMP's Days Sales Outstanding is ranked lower than
79% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CEMP: 114.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.37  Med: 89.03 Max: 124.84
Current: 114.49
56.37
124.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
CEMP's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CEMP: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CEMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -314.5  Med: -270.1 Max: -16.4
Current: -16.4
-314.5
-16.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.30
CEMP's Price-to-Net-Cash is ranked higher than
96% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CEMP: 1.30 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CEMP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.83  Med: 4.71 Max: 16.1
Current: 1.3
0.83
16.1
Price-to-Net-Current-Asset-Value 1.24
CEMP's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CEMP: 1.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CEMP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.8  Med: 4.57 Max: 14.51
Current: 1.24
0.8
14.51
Price-to-Tangible-Book 1.24
CEMP's Price-to-Tangible-Book is ranked higher than
92% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CEMP: 1.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CEMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.8  Med: 4.57 Max: 14.43
Current: 1.24
0.8
14.43
Price-to-Median-PS-Value 0.21
CEMP's Price-to-Median-PS-Value is ranked higher than
91% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CEMP: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CEMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 1.02 Max: 1.55
Current: 0.21
0.17
1.55
Earnings Yield (Greenblatt) % -833.20
CEMP's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CEMP: -833.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CEMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -833.33  Med: 263.75 Max: 25091.4
Current: -833.2
-833.33
25091.4

More Statistics

Revenue (TTM) (Mil) $20.21
EPS (TTM) $ -2.17
Beta0.99
Short Percentage of Float12.32%
52-Week Range $2.55 - 26.95
Shares Outstanding (Mil)52.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 12 3 19
EPS ($) -0.89 -0.47 -0.23
EPS without NRI ($) -0.89 -0.47 -0.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Cempra Presents Data on Ophthalmic Solithromycin at ARVO May 10 2017 
Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update Apr 28 2017 
Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromyci Apr 21 2017 
Cempra to Report First Quarter 2017 Financial Results Apr 13 2017 
Cempra Withdraws Solithromycin Marketing Authorization Application in Europe Mar 28 2017 
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options Mar 13 2017 
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
[$$] Health-Care Investor Agent Capital Seeks $100 Million Fund May 16 2017
ETFs with exposure to Cempra, Inc. : May 15, 2017 May 15 2017
Cempra Presents Data on Ophthalmic Solithromycin at ARVO May 10 2017
Cempra, Inc. :CEMP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 May 03 2017
Edited Transcript of CEMP earnings conference call or presentation 28-Apr-17 12:45pm GMT May 02 2017
Cempra loses executive, but eyes FDA feedback May 01 2017
Today's Research Reports on Stocks to Watch: Cempra and PhaseRx May 01 2017
Cempra reports 1Q loss Apr 28 2017
Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update Apr 28 2017
Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of... Apr 21 2017
Cempra to Report First Quarter 2017 Financial Results Apr 13 2017
Cempra to Present at the 16th Annual Needham & Company Healthcare Conference Mar 29 2017
Cempra Withdraws Solithromycin MAA in Europe Mar 28 2017
For Chapel Hill's Cempra, no European launch for now Mar 28 2017
Biotech Premarket Movers: Cempra, Tesaro, Editas Mar 28 2017
Cempra Withdraws Solithromycin Marketing Authorization Application in Europe Mar 28 2017
ETFs with exposure to Cempra, Inc. : March 27, 2017 Mar 27 2017
Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)